4//SEC Filing
KEYSER D JEFFREY 4
Accession 0001213900-20-015034
CIK 0001763950other
Filed
Jun 14, 8:00 PM ET
Accepted
Jun 15, 5:16 PM ET
Size
10.3 KB
Accession
0001213900-20-015034
Insider Transaction Report
Form 4
KEYSER D JEFFREY
Director
Transactions
- Conversion
Common Stock
2020-06-15+31,927→ 41,927 total - Conversion
Series A Preferred Stock
2020-06-15−18,349→ 0 total→ Common Stock (31,927 underlying) - Award
Stock Option
2020-06-15+9,135→ 9,135 totalExercise: $15.00→ Common Stock (9,135 underlying)
Footnotes (3)
- [F1]In connection with the Issuer's initial public offering ("IPO"), the Issuer effected a 1.74-for-1 stock split on its outstanding common stock, which became effective immediately prior to the closing of the Issuer's IPO ("Stock Split"). The share amounts reflect the Stock Split.
- [F2]In connection with the IPO, the 18,349 shares of Series A Preferred Stock held by the Reporting Person were automatically converted for no additional consideration into 31,927 shares of common stock immediately prior to the closing of the Issuer's IPO.
- [F3]The Reporting Person was granted options to purchase 9,135 shares of the Issuer's common stock at the exercise price equal to the price per share sold in the Issuer's IPO. The options granted will vest in equal monthly increments over a 36 month period commencing upon the closing of the Issuer's IPO, which is the grant date of the options. Under the Amended and Restated 2018 Equity Incentive Plan, the options may not be exercised after the tenth anniversary of the grant date.
Documents
Issuer
Lantern Pharma Inc.
CIK 0001763950
Entity typeother
Related Parties
1- filerCIK 0001393516
Filing Metadata
- Form type
- 4
- Filed
- Jun 14, 8:00 PM ET
- Accepted
- Jun 15, 5:16 PM ET
- Size
- 10.3 KB